This 2001 review analyzed long-term (≥36 weeks) placebo-controlled trials of obesity pharmacotherapy published since 1960. The study found that weight loss attributable to pharmacotherapy over 36–52 weeks was approximately 8.1% (7.9 kg) for phentermine resin, 5.0% (4.3 kg) for sibutramine, 3.4% (3.4 kg) for orlistat, and −1.5% (−1.5 kg) for
This 2004 case series examines the clinical experiences of eight adult patients who utilized pharmacotherapy for obesity management over a period exceeding 10 years. The medications used included agents such as phentermine and sibutramine. Patients reported sustained weight loss, perceived benefits, and an absence of significant side effects. Notably, there
This 2013 study analyzed national trends in the use of prescription antiobesity medications in the U.S. from 1991 to 2011. Findings revealed that phentermine dominated prescriptions, accounting for 86.6% in 2011. Usage peaked in 1996 and declined following the withdrawal of fenfluramine and dexfenfluramine due to safety concerns. By 2011,
This 2005 randomized, controlled trial assessed the efficacy of combining sibutramine (15 mg daily) with lifestyle modification in 224 obese adults over one year. Participants were assigned to one of four groups: sibutramine alone, lifestyle modification alone, sibutramine plus lifestyle modification, or sibutramine plus brief lifestyle counseling. All groups followed
